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Circulating high-density lipoprotein (HDL) comprises a spectrum of lipoproteins ranging from nascent discoidal 
to mature spherical particles, the former having preβ- and the 
latter α-electrophoretic mobility.1 Irrespective of their shape, 
size, or composition, all HDL particles contain either a sin-
gle copy or multiple copies of apolipoprotein A-I (apoA-I), 
a polypeptide with an apparent molecular weight of 28 000 
kDa. Both lipid-free apoA-I and the nascent lipid-poor preβ-
HDL are the primary acceptors of cholesterol effluxed via the 
ATP-binding cassette transporter A1 (ABCA1) from mac-
rophage foam cells,2 and so play critical roles in promoting 
reverse cholesterol transport in vivo. Although the circulating 
blood contains only minute amounts of preβ-HDL, these par-
ticles are enriched in human interstitial fluids.3 This appears 
also to apply to the arterial intimal fluid, with a concentration 
of HDL almost 40% of that in plasma, and in which most of 
the HDL particles have a density comparable to the very high–
density lipoprotein subclass and contain only apoA-I.4
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Objective—Apolipoprotein A-I (apoA-I) has been shown to possess several atheroprotective functions, including inhibition 
of inflammation. Protease-secreting activated mast cells reside in human atherosclerotic lesions. Here we investigated the 
effects of the neutral proteases released by activated mast cells on the anti-inflammatory properties of apoA-I.
Approach and Results—Activation of human mast cells triggered the release of granule-associated proteases chymase, 
tryptase, cathepsin G, carboxypeptidase A, and granzyme B. Among them, chymase cleaved apoA-I with the greatest 
efficiency and generated C-terminally truncated apoA-I, which failed to bind with high affinity to human coronary artery 
endothelial cells. In tumor necrosis factor-α–activated human coronary artery endothelial cells, the chymase-cleaved apoA-I 
was unable to suppress nuclear factor-κB–dependent upregulation of vascular cell adhesion molecule-1 (VCAM-1) and 
to block THP-1 cells from adhering to and transmigrating across the human coronary artery endothelial cells. Chymase-
cleaved apoA-I also had an impaired ability to downregulate the expression of tumor necrosis factor-α, interleukin-1β, 
interleukin-6, and interleukin-8 in lipopolysaccharide-activated GM-CSF (granulocyte-macrophage colony-stimulating 
factor)– and M-CSF (macrophage colony-stimulating factor)–differentiated human macrophage foam cells and to inhibit 
reactive oxygen species formation in PMA (phorbol 12-myristate 13-acetate)–activated human neutrophils. Importantly, 
chymase-cleaved apoA-I showed reduced ability to inhibit lipopolysaccharide-induced inflammation in vivo in mice. 
Treatment with chymase blocked the ability of the apoA-I mimetic peptide L-4F, but not of the protease-resistant D-4F, 
to inhibit proinflammatory gene expression in activated human coronary artery endothelial cells and macrophage foam 
cells and to prevent reactive oxygen species formation in activated neutrophils.
Conclusions—The findings identify C-terminal cleavage of apoA-I by human mast cell chymase as a novel mechanism 
leading to loss of its anti-inflammatory functions. When targeting inflamed protease-rich atherosclerotic lesions with 
apoA-I, infusions of protease-resistant apoA-I might be the appropriate approach.  (Arterioscler Thromb Vasc Biol. 
2016;36:274-284. DOI: 10.1161/ATVBAHA.115.306827.)
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Current data suggest that by regulating cellular cholesterol 
homeostasis, HDL can also regulate inflammatory responses 
in various types of cells that have been activated by proinflam-
matory stimuli in the arterial wall.5 Importantly, proinflamma-
tory activation of the endothelium is regarded critical for the 
initiation and progression of atherosclerosis. Mechanistically, 
dysfunctional endothelium may arise when activated endothe-
lial cells (ECs) express the vascular cell adhesion molecule-1 
(VCAM-1) or the intercellular adhesion molecule-1 that trig-
ger leukocyte adhesion to the activated ECs.6 Both lipid-free 
apoA-I and HDL particles have been shown to exert potent 
anti-inflammatory effects on activated cultured ECs of human, 
bovine, or murine origin7–9 and also on other cell types involved 
in atherogenesis, such as human monocytes10 and monocyte-
derived macrophages.11,12 The anti-inflammatory actions of 
apoA-I and HDL have been shown to involve attenuation of 
nuclear factor-κB (NF-κB) activation in various types of human 
ECs when they are exposed to proinflammatory stimuli, such 
as tumor necrosis factor (TNF-α), lipopolysaccharide (LPS), 
or palmitic acid.8,13–15 ApoA-I exhibits anti-inflammatory func-
tions also in vivo, as demonstrated by injecting into rabbits 
apoA-I in the lipid-free form, or as a component of discoidal 
reconstituted HDL (rHDL) or of mature spherical HDL.16,17
In atherosclerotic lesions, the infiltrating inflammatory 
cells include mast cells, which upon activation and ensuing 
degranulation release neutral serine proteases, among them 
chymase and tryptase, both capable of cleaving the various 
apolipoproteins present in HDL particles.18 Importantly, mast 
cell chymase efficiently cleaves lipid-free apoA-I and depletes 
preβ-HDL particles, and so blocks their ability to promote 
ABCA1-dependent cholesterol efflux from macrophage foam 
cells in vitro and in vivo.19–22 Here we hypothesized that pro-
teolytic cleavage of apoA-I by chymase could also influence 
its anti-inflammatory activities. Our data demonstrate that 
C-terminal cleavage of apoA-I by mast cell chymase impairs 
its ability to suppress proinflammatory responses in vitro and 
in vivo. Similarly, plasmin-treated apoA-I also failed to exert 
anti-inflammatory action on activated human coronary artery 
endothelial cells (HCAECs) in culture. The present study dis-
closes a pathophysiological link between proteolytic cleav-
age of apoA-I and vascular inflammation.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Proteolysis Impairs the Ability of 
ApoA-I to Attenuate TNF-α-Induced 
VCAM-1 Expression in HCAECs
HCAECs were preincubated with lipid-free apoA-I, then 
exposed to TNF-α, and the expression of VCAM-1 pro-
tein, as a cell surface marker of proinflammatory activa-
tion,23 was analyzed by flow cytometry. Stimulation with 
TNF-α shifted the fluorescence peak from left to right, 
indicating upregulation of VCAM-1, whereas pretreat-
ment with apoA-I partially prevented it, as indicated by the 
lesser right-shift of the fluorescence peak (Figure 1A). To 
evaluate the effect of proteolysis on this anti-inflammatory 
function of apoA-I, we incubated apoA-I with recom-
binant human chymase and compared the abilities of the 
untreated and chymase-treated apoA-I to inhibit TNF-α-
dependent VCAM-1 expression. As shown in Figure 1B, 
addition of increasing concentrations of untreated apoA-I 
to the cultured HCAECs suppressed VCAM-1 upregulation 
in a dose-dependent fashion, with maximal suppression 
observed at 50 μg/mL. In contrast, chymase-treated apoA-I 
totally failed to prevent the TNF-α-dependent induction of 
VCAM-1 expression.
Analysis of the apoA-I degradation products by Western 
blotting indicated that chymase completely depleted the 
full-length apoA-I and generated a large-sized polypeptide 
band which had lost immunoreactivity against a monoclonal 
antibody recognizing a C-terminal epitope encompassing the 
amino acid residues 211–220 (Figure 1C, left). In agreement 
with a previous report, chymase did not modify apoA-I reac-
tivity with a monoclonal antibody specific for the N-terminal 
region (amino acids 2–8).20 A similar degradation pattern 
was observed when apoA-I was treated with conditioned cul-
ture medium in which human mast cells had been activated 
to degranulate and release a complex mixture of granule neu-
tral proteases, including chymase.24 Accordingly, incubation 
of apoA-I with such preconditioned medium resulted in loss 
of C-terminal reactivity in a concentration-dependent man-
ner (Figure 1C, right). We further determined the individual 
contribution of each of the 5 released proteases (chymase, 
tryptase, cathepsin G, carboxypeptidase A3, and granzyme 
B) to apoA-I degradation. For this purpose, specific prote-
ase inhibitors were used. Regarding inhibition of the 2 chy-
motryptic enzymes, that is, chymase and cathepsin G, the 
chymase inhibitor specifically inhibited chymase, whereas 
the cathepsin G inhibitor was found to inhibit both chymase 
and cathepsin G. We observed that selective inhibition of 
chymase almost completely blocked apoA-I degradation, 
whereas the combined inhibition chymase and cathepsin G 
completely blocked it. In contrast, inhibition of tryptase, 
carboxypeptidase A3, or granzyme B only slightly inhibited 
proteolysis or had no effect (Figure I in the online-only Data 
Supplement). These results indicated that among the neutral 
proteases released by activated human mast cells, chymase 
was the main protease responsible for the mast cell–depen-
dent loss of the anti-inflammatory function of apoA-I in 
HCAECs. This finding prompted us to perform subsequent 
experiments with chymase alone.
Nonstandard Abbreviations and Acronyms
(A-I)rHDL apoA-I-containing reconstituted HDL
ABCA1 ATP-binding cassette transporter A1
apoA-I apolipoprotein A-I
EC endothelial cells




TNFα tumor necrosis factor-α
VCAM-1 vascular cell adhesion molecule-1
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Lipidation of ApoA-I Renders It Partly 
Resistant to Chymase-Dependent Loss of Its 
Anti-Inflammatory Effects on HCAECs
To examine the effect of apoA-I lipidation on the ability of chy-
mase to attenuate its anti-inflammatory properties, we studied 
apoA-I-containing reconstituted HDL ((A-I)rHDL) particles 
that have been widely used to mimic the naturally occurring 
preβ-HDL.25 For this purpose, we prepared 3 species of discoi-
dal (A-I)rHDL with increasing amounts of phospholipids and 
constant amounts of cholesterol and apoA-I: rHDL-1, rHDL-
2, and rHDL-3 (Table I in the online-only Data Supplement). 
Similar to proteolysis of lipid-free apoA-I with chymase, pro-
teolysis of lipidated apoA-I generated a polypeptide band with 
an apparent molecular weight slightly lower than that of intact 
apoA-I (Figure 2A, top). Yet, the degree of lipidation was 
inversely related to the degree of proteolysis (Figure 2A, bot-
tom), suggesting that lipidation progressively masked the chy-
mase cleavage sites of apoA-I. Next, we examined the effect 
of chymase on the anti-inflammatory properties of the vari-
ous (A-I)rHDL preparations. When activated HCAECs were 
preincubated with any of the untreated (A-I)rHDL species, the 
levels of VCAM-1 mRNA and protein were reduced to levels 
comparable to those observed when lipid-free apoA-I was used 
(Figure 2B, top and middle). Moreover, any of the untreated 
(A-I)rHDL reduced adhesion of THP-1 monocytes to the 
activated HCAECs to the levels observed in the nonactivated 
control cells (Figure 2B, bottom). Cleavage of apoA-I in (A-I)
rHDLs affected the ability of these particles to inhibit surface 
VCAM-1 protein expression, and it appeared that the stronger 
apoA-I degradation (rHDL-1>rHDL-2>rHDL-3), the weaker 
its inhibitory effect on VCAM-1 protein expression (P<0.05 
for trend). However, all of the proteolyzed rHDLs had lost to 
a similar extent their capacity to reduce VCAM-1 mRNA and 
monocyte adhesion to TNF-α-activated HCAECs (Figure 2B, 
top and bottom), suggesting that even a minor degree of prote-
olysis may have significantly affected particle integrity and the 
specific conformational characteristics of apoA-I in (A-I)rHDL 
particles that were essential for these particular apoA-I-depen-
dent effects. Importantly, analysis with nondenaturing electro-
phoresis revealed that incubation of (A-I)rHDLs with chymase 
resulted in significant changes in protein staining pattern and 
particle size distribution (Figure IIA and IIB in the online-only 
Figure 1. Chymase treatment abolishes the anti-inflammatory activity of apolipoprotein A-I (apoA-I) on activated human coronary artery 
endothelial cells (HCAECs). A, HCAECs were preincubated for 16 h in the absence (buffer) or presence of apoA-I (50 μg/mL) and then acti-
vated with tumor necrosis factor-α (TNF-α; 10 ng/mL) for 5 h. Nonactivated cells were incubated in medium alone for 21 h (control). Cell 
surface vascular cell adhesion molecule-1 (VCAM-1) protein was determined by flow cytometry. Data are representative of 6 independent 
experiments. B, ApoA-I (1 mg/mL) was treated for 6 h in the absence (untreated) or the presence (chymase-treated) of chymase (0.5 μg=40 
BTEE units/mL). HCAECs were preincubated with increasing concentrations of the untreated or chymase-treated apoA-I and then activated 
with tumor necrosis factor-α (TNF-α), as described in A. TNF-α-induced VCAM-1 surface protein expression was analyzed by flow cytom-
etry and expressed as percentage of its expression levels in TNF-α-activated cells preincubated in the absence of apoA-I, which was set as 
100%. Data represent the means±SD from 3 to 4 independent experiments performed in duplicate. *P<0.01 denotes statistical significance 
between cells preincubated with untreated or chymase-treated apoA-I. C, ApoA-I was incubated with the indicated activities (BTEE units) of 
recombinant human chymase or chymase-containing human mast cell–conditioned medium for 6 h, after which the incubation was stopped 
by adding soybean trypsin inhibitor. Proteins in the incubation mixtures were resolved in 12.5% SDS-PAGE and detected by Coomassie 
Blue or immunoblotted with anti-human apoA-I polyclonal antibody or with anti-human apoA-I monoclonal antibodies recognizing either a 
C-terminal (amino acids 211–220) or an N-terminal (amino acids 2–8) region of apoA-I. MFI indicates median fluorescence intensity.
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Data Supplement). Consistent with previous reports,20,26 and 
in contrast to lipid-free apoA-I and rHDLs, apoA-I in mature 





was poorly degraded by chymase, and the particles maintained 
their ability to inhibit TNF-α-induced VCAM-1 expression, 
despite treatment with chymase (Figure IIIA and IIIB in the 
online-only Data Supplement). It is plausible that the insen-
sitivity of apoA-I in mature HDL particles is because of inac-
cessibility of proteases to the apolipoprotein, which is partially 
embedded in the surface phospholipid layer of the particles. 
Interestingly, neither chymase nor cathepsin G, but rather α-1 
antitrypsin, has been found to be a component of total (unfrac-
tionated) HDL and the HDL
3
 fraction derived from circulating 
plasma or from atherosclerotic carotid tissue,27 and so provid-
ing an additional explanation for the protease insensitivity of 
apoA-I in these particles.
Proteolysis of ApoA-I by Plasmin or Cathepsin S 
Impairs Its Anti-Inflammatory Effects on HCAECs
We evaluated the effect of other proteases known to be 
present in atherosclerotic lesions, namely plasmin and 
cathepsin S,28,29 on the anti-inflammatory activity of apoA-I 
in cultured HCAECs. Similar to chymase, plasmin cleaved 
the C-terminal region, resulting in the formation of a frag-
ment containing the N-terminal region, whereas cathepsin S 
completely degraded apoA-I (Figure IVA in the online-only 
Data Supplement). Importantly, similar to chymase, treat-
ment of apoA-I with either of the 2 proteases resulted in 
complete loss of its ability to inhibit VCAM-1 expression 
in TNF-α-activated HCAECs and to prevent the adhesion of 
THP-1 monocytes to these cells (Figure IVB in the online-
only Data Supplement).
Chymase Treatment of ApoA-I Impairs Its 
Ability to Attenuate NF-κB Activation, to Bind 
to HCAECs, and to Prevent Transendothelial 
Migration of THP-1 Monocytes
Next we examined the effect of chymase treatment of lipid-free 
apoA-I on NF-κB activation, a dominant signal transduction 
pathway upregulating a variety of chemokines and adhesion 
molecules in human ECs.30 Pretreatment of HCAECs with 
untreated apoA-I significantly attenuated TNF-α-mediated 
Figure 2. Effect of apolipoprotein A-I (apoA-I) lipidation on its sensitivity to proteolysis and on the ability of untreated and chymase-
treated apoA-I to influence vascular cell adhesion molecule-1 (VCAM-1) expression in and THP-1 adhesion to tumor necrosis factor-α 
(TNF-α)-activated human coronary artery endothelial cells (HCAECs). A, Top, ApoA-I and discoidal apoA-I-containing reconstituted high-
density lipoprotein ((A-I)rHDLs) with 3 different degrees of lipidation (see Table I in the online-only Data Supplement) were incubated in 
the absence or presence of recombinant chymase, and the proteins in the incubation mixtures were analyzed, as described in Figure 1. 
Bottom, ApoA-I degradation was expressed as a percentage of the intensity of the intact band in the proteolyzed samples relative to the 
corresponding untreated sample and plotted against the lipid/protein mass ratio of the various (A-I)rHDL preparations. B, HCAECs were 
preincubated for 16 h with the various untreated or chymase-treated apoA-I or (A-I)rHDL species (50 μg/mL, each) and then activated 
with tumor necrosis factor-α (TNF-α), as described in Figure 1. Nonactivated cells (control) and TNF-α-activated cells preincubated in 
only medium (buffer) acted as references. Vascular cell adhesion molecule-1 (VCAM-1) mRNA levels (top, fold change relative to control) 
and surface protein expression (middle, % of buffer) were evaluated in the TNF-α-activated cells. In a separate experiment, HCAECs that 
had been preincubated with the various apoA-I-containing preparations were further incubated for 1 h with fluorescently labeled THP-
1cells, and the fluorescence of HCAECs-bound THP-1 cells was then measured (bottom). The fluorescence signal of the TNF-α-activated 
HCAECs was expressed as percentage of the basal signal from the nonactivated cells (control) which was set as 100%. Data shown 
in each panel represent the means±SD from 3 to 4 independent experiments performed in triplicate wells. **P<0.05; *P<0.01; #P<0.01 
(untreated apoA-I-containing preparations vs buffer).
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NF-κB activation, as indicated by suppression of nuclear 
translocation of the p65 subunit of NF-κB (Figure 3A), a 
finding in agreement with previous reports.13,14 In contrast, 
treatment with chymase abolished the inhibitory effect of 
apoA-I on NF-κB activation, indicating that the intactness 
of apoA-I is a prerequisite for the inhibition of this signaling 
pathway. To further investigate the mechanisms involved in 
the chymase-dependent loss of the anti-inflammatory effects 
of apoA-I, we compared binding of untreated and chymase-
treated 125I-labeled apoA-I to HCAECs. We found that chy-
mase treatment severely blunted (≥80%) the high-affinity 
binding of apoA-I to HCAECs (Figure 3B), strongly suggest-
ing that reduced interaction of apoA-I with the cell membrane 
was necessary for loss of the anti-inflammatory effect. The 
above finding also agrees with the observed strong reduc-
tion of specific binding to bovine aortic endothelial cells of 
C-terminal deletion mutants of apoA-I.31
We further examined the effect of untreated and chy-
mase-treated apoA-I on transmigration of THP-1 monocytes 
across monolayers of TNF-α-activated HCAECs using the 
transwell system, which mimics the human endothelium 
in vivo. We found that, regardless of whether adding to the 
apical or basolateral compartment, chymase-treated apoA-I 
failed to attenuate THP-1 transmigation across the activated 
HCAECs (Figure 3C). Interestingly, untreated apoA-I sig-
nificantly prevented the endothelial transmigration of THP-1 
when placed in the apical compartment, whereas a slight, 
but nonsignificant decrease was observed when apoA-I was 
added to the basolateral compartment. The smaller effect of 
untreated apoA-I could be possibly because of much lower 
basolateral than apical binding of apoA-I, which may be 
partly caused by sterical hindrance binding to ECs because 
of the presence of a porous membrane and coated matrix in 
the transwell insert.32
Figure 3. Proteolysis of apolipoprotein A-I (apoA-I) impairs its ability to attenuate nuclear factor-κB (NF-κB) activation to bind to human 
coronary artery endothelial cells (HCAECs) and to prevent transmigration of THP-1 monocytes across HCAEC monolayer. A, HCAECs 
were incubated for 16 h with untreated or chymase-treated apoA-I and then activated with tumor necrosis factor-α (TNF-α) for 15 min. 
Nonactivated cells (control) and TNF-α-activated cells preincubated in only medium (buffer) acted as a reference. Nuclear NF-κB p65 
activity was determined by measuring nuclear translocation of the NF-κB p65 subunit. The basal activity of the nonactivated HCAECs 
(control) was set as 1. Data represent the means±SD from triplicate wells and are representative of 2 independent experiments. *P<0.05. 
B, ApoA-I was labeled with 125I and then treated with chymase as described in Figure 1B. HCAECs were incubated with the indicated 
concentrations of 125I-labeled untreated or chymase-treated apoA-I in the absence or presence of a 40-fold excess of untreated apoA-I 
for 2 h at 4°C. High-affinity binding of 125I-apoA-I to HCAECs was calculated by subtracting the values of the nonspecific binding from the 
total binding. A representative pair of binding curves is shown in the top panel. Data (mean±SD) from 4 independent experiments from 
duplicate wells are expressed as percentages of untreated apoA-I (bottom). *P<0.01. C, Confluent HCAEC monolayers grown on a tran-
swell insert were first incubated with untreated or chymase-treated apoA-I added either to the apical or basolateral compartment, then 
activated with TNF-α for 5 h, and finally incubated with fluorescently labeled THP-1 cells added to the apical compartment. Migration 
across the endothelial monolayer of the cells was quantified by measuring the fluorescence signal of the transmigrated cells. Migration in 
the absence of any additions was designated as 100% (control). Data shown represent the means±SD from 3 independent experiments 
performed in triplicate wells. *P<0.05; #P<0.05 (untreated apoA-I vs buffer).
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Chymase Treatment of ApoA-I Reduces Its Ability 
to Inhibit Expression of Proinflammatory Genes 
in HCAECs and in Macrophages and to Induce 
Cholesterol Efflux From Macrophage Foam Cells
We next examined the effect of chymase-treated lipid-free 
apoA-I on selected proinflammatory genes in TNF-α-activated 
HCAECs. TNF-α strongly increased mRNA levels of intercellu-
lar adhesion molecule-1, cyclooxygenase-2 (COX-2), and inter-
leukin (IL)-8, although only slightly affected that of IL-6 (Figure 
4A–4D). Treatment of HCAECs before activation with untreated, 
but not with chymase-treated, apoA-I significantly decreased the 
TNF-α-dependent induction of COX-2, IL-6, and IL-8 mRNA 
expression. In contrast, neither untreated nor chymase-treated 
apoA-I had any effect on intercellular adhesion molecule-1 
expression. We also determined the effect of the chymase-treated 
apoA-I on the expression of cytokines in LPS-activated mac-
rophage foam cells. For this purpose, human monocytes were 
allowed to differentiate into macrophages either in the presence 
of GM-CSF (granulocyte-macrophage colony-stimulating fac-
tor) or M-CSF (macrophage colony-stimulating factor) to obtain 
the GM-Mac and M-Mac subpopulations, which have their coun-
terparts in human atherosclerotic lesions,33 and finally incubated 
with acetyl-LDL. To avoid any LPS binding to apoA-I,34 the 
foam cells were preincubated with untreated or chymase-treated 
apoA-I, then extensively washed, and finally challenged with 
LPS. Similar to the effects observed in HCAECs, preincuba-
tion with the untreated apoA-I, but not with the chymase-treated 
apoA-I, significantly suppressed LPS-induced upregulation of 
mRNA levels of proinflammatory cytokines, namely of TNF-α, 
IL-1β, IL-6, and IL-8 in both macrophage foam cell subtypes 
(Figure 4E–4L). To investigate how the loss of the anti-inflam-
matory effect of apoA-I by chymase modification was related 
to the known chymase-dependent loss of the cholesterol efflux 
ability of apoA-I, we also determined cholesterol efflux capacity 
of chymase-treated apoA-I in the GM-Mac- and M-Mac-derived 
foam cells. Consistent with previous studies,19,20 treatment of 
Figure 4. Proteolysis of apolipoprotein A-I (apoA-I) reduces its ability to downregulate the expression of proinflammatory genes in human 
coronary artery endothelial cells (HCAECs) and in human GM-Mac and M-Mac macrophage subpopulations and to promote cholesterol 
efflux from the macrophages. A-D, HCAECs were preincubated with untreated or chymase-treated apoA-I and then activated with tumor 
necrosis factor-α (TNF-α), as described in Figure 1. Nonactivated cells (control) and TNF-α-activated cells preincubated in only medium 
(buffer) acted as a reference. The mRNA levels of intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2), interleukin (IL)-
6, and IL-8 in HCAECs were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and expressed as fold changes 
relative to the control cells. Data represent the means±SD from 3 independent experiments performed in duplicate. *P<0.01. E-L, Human 
monocyte-derived macrophages were differentiated in the presence of GM-CSF (granulocyte-macrophage colony-stimulating factor) or 
M-CSF (macrophage colony-stimulating factor) into GM-Mac and M-Mac subtypes, respectively, and then converted into foam cells by 
incubation with acetyl low density lipoprotein (LDL). The cells were then incubated for 3 h with untreated or chymase-treated apoA-I (50 
μg/mL, each), washed, and activated for 3 h with lipopolysaccharide (LPS). Nonactivated cells (control) and LPS-activated cells prein-
cubated in only medium (buffer) acted as references. LPS-induced mRNA levels of TNF-α, IL-1β, IL-6, and IL-8 in GM-Mac and M-Mac 
foam cells were evaluated by qRT-PCR and expressed as fold changes relative to the control cells. *P<0.01; **P<0.05. M, GM-Mac- and 
M-Mac-derived foam cells were incubated with untreated or chymase-treated apoA-I (50 μg/mL, each) for 3 h, the media were collected, 
centrifuged to remove cellular debris, and the radioactivity of each supernatant was determined by liquid scintillation counting. Cells were 
solubilized, and radioactivity was determined in the cell lysates. Cholesterol efflux was calculated as dpmmedium/(dpmcells+dpmmedium)×100. 
Data represent the means±SD from triplicate wells and are representative of 2 independent experiments. *P<0.01.
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apoA-I with chymase decreased its ability to induce cholesterol 
efflux from macrophage foam cells (Figure 4M). Taken together, 
cleavage of apoA-I with chymase impaired both its anti-inflam-
matory and cholesterol efflux-inducing activities.
Chymase Treatment of ApoA-I Reduces Its 
Anti-Inflammatory Properties In Vivo
To learn whether chymase would also affect the anti-inflam-
matory properties of lipid-free apoA-I in vivo, we used the 
well-established mouse model of LPS-induced inflammation, 
in which apoA-I has been shown to exert its anti-inflammatory 
properties.7,35,36 We found that LPS administration remarkably 
increased the levels of 2 circulating proinflammatory mediators 
(TNF-α and IL-1β). Concurrent treatment of mice with both 
LPS and lipid-free apoA-I significantly reduced the level of 
TNF-α and IL-1β (Figure 5A and 5B), consistent with the well-
known anti-inflammatory effect of apoA-I on LPS-induced 
inflammation in vivo.35 Importantly, concurrent treatment of 
mice with LPS and chymase-treated apoA-I failed to signifi-
cantly diminish the levels of either TNF-α or IL-1β, indicating 
that the proteolytic degradation of apoA-I by chymase impaired 
its anti-inflammatory properties (Figure 5A and 5B). To obtain 
further insight into the mechanisms by which chymase impaired 
anti-inflammatory properties of apoA-I in vivo, we determined 
endotoxin activity using the limulus amebocyte lysate assay. 
In line with previous studies demonstrating that both HDL and 
apoA-I exert their anti-inflammatory properties in vivo via their 
ability to bind to LPS and neutralize endotoxin,35–37 we found 
that apoA-I strongly neutralized LPS endotoxin activity in vitro 
(Figure 5C). In sharp contrast, chymase-treated apoA-I had 
totally lost the ability to neutralize endotoxin activity.
Chymase Treatment Does Not Blunt the 
Anti-Inflammatory Effects of D-4F on 
HCAECs, Neutrophils, and Macrophages
The apoA-I mimetic peptide L-4F exerts potent anti-inflam-
matory effects by reducing the chemotactic activity of human 
aortic ECs for monocytes.38 Given the cleavage specificity of 
chymase, a chymotryptic protease, and the arrangement of aro-
matic amino acid residues in the 4F structure that determines 
its functional properties,39 we considered that chymase could 
cleave L-4F, so resulting in its functional inactivation. As a con-
trol, we used D-4F, which is resistant to cleavage by mammalian 
proteases.40 Both untreated L-4F and D-4F decreased VCAM-1 
protein expression in TNF-α-activated HCAECs to a similar 
extent (Figure 6A). However, when chymase-treated L-4F and 
D-4F were compared, we found that the former had lost, but 
the latter had maintained its anti-inflammatory effect. Because 
the remarkable anti-inflammatory properties of both 4F species 
appear to be accounted for their ability to bind proinflammatory 
oxidized lipids,38 we also evaluated the effect of chymase on 
their antioxidant effects in PMA (phorbol 12-myristate 13-ace-
tate)–activated neutrophils. We found that, although apoA-I and 
both mimetic peptides significantly diminished superoxide pro-
duction by the activated neutrophils in a dose-dependent man-
ner, chymase treatment fully abolished the antioxidant effect 
of apoA-I and L-4F, but not that of D-4F (Figure 6B). Similar 
to findings observed with HCAECs and neutrophils, both 
untreated and chymase-treated D-4F significantly decreased 
to a similar extent the mRNA levels of the proinflammatory 
cytokines (IL-1β, IL-6, and IL-8) in LPS-activated macrophage 
foam cells of the 2 phenotypes (GM-Mac and M-Mac) (Figure 
6C–CJ). Interestingly, unlike apoA-I, D-4F failed to decrease 
mRNA levels of TNF-α in either macrophage phenotype.
Discussion
The present study demonstrates that protease-dependent loss 
of the C-terminal region of apoA-I is sufficient to fully inhibit 
its anti-inflammatory properties both in vitro and in vivo. 
The enzymes capable of such cleavage comprised chymase 
and plasmin, the former known to be secreted by vascular 
mast cells41 and the latter by vascular smooth muscle cells 
and ECs.18 The repertoire of cell-derived extracellular prote-
ases present in the human atherosclerotic arterial intima and 
Figure 5. Proteolysis of apolipoprotein A-I 
(apoA-I) impairs its ability to inhibit lipopolysac-
charide (LPS)-induced inflammation in vivo 
and to neutralize endotoxin activity of LPS in 
vitro. Mice (6–8 per group) were randomized to 
receive vehicle (PBS), LPS (1 mg/kg), LPS (1 
mg/kg) plus apoA-I (10 mg/kg), or LPS (1 mg/
kg) plus chymase-treated apoA-I (10 mg/kg). 
After 3 h, serum was collected, and TNF-α (A) 
and IL-1β (B) concentrations were measured. 
Data are means±SD, *P<0.05. C, LPS (1 μg/
mL) was mixed with untreated apoA-I and 
chymase-treated apoA-I (10 μg/mL) and endo-
toxin activity was measured with kinetic colo-
rimetric limulus amebocyte lysate (LAL) assay. 
Data represent the means±SD from triplicate 
wells and are representative of 2 independent 
experiments.
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capable of cleaving the C-terminal domain of apoA-I extends 
to the members of the matrix metalloproteinase family-3, -7, 
and -12.18 Altogether, these findings suggest that an inflamed 
atherosclerotic lesion is a compartment in which protease-
dependent attenuation of the anti-inflammatory functions of 
HDL could take place.
The structure–function relationships involved in the 
mechanisms determining the anti-inflammatory activities of 
apoA-I and HDL are manifold. According to current notions, 
apoA-I suppresses the expression of surface adhesion mol-
ecules in ECs in vitro via interaction with ABCA1, which 
initiates a cascade of intracellular signaling events that are 
thought to involve lipid efflux–dependent disruption of lipid 
rafts.5,42 Moreover, apoA-I has been shown to induce COX-2 
expression and PGI-2 (prostacyclin) release in unstimulated 
HUVECs via interaction with ABCA1,43 revealing functional 
interactions between apoA-I and ABCA1. Furthermore, it 
was recently shown that the anti-inflammatory and antioxi-
dant effects of the apoA-I mimetic peptide 5A are mediated 
via the ABCA1 transporter and NF-κB signaling pathways 
in HCAECs.14 Thus, it is likely that, besides being involved 
in the transcytotic pathway of lipid-free apoA-I through 
ECs,32,44 binding of apoA-I to ABCA1 also essentially con-
tributes to the anti-inflammatory actions of lipid-free apoA-I 
in HCAECs. Interestingly, the C-terminal domain of apoA-
I has been shown to be required for endothelial binding and 
transendothelial transport of lipid-free apoA-I.31 Here, we 
have demonstrated that cleavage of the C-terminal domain of 
apoA-I by chymase prevented binding of apoA-I to HCAECs 
with high affinity and caused its failure to suppress the initia-
tion of the NF-κB-mediated downstream inflammatory sig-
naling in TNF-α-activated HCAECs. Similarly, glycation of 
apoA-I which modifies the conformation of epitopes present 
in C-terminal and central regions of apoA-I has been shown to 
impair its anti-inflammatory effects on HCAECs.13,45
Regarding the effect of chymase treatment of apoA-I on 
its ability to interact with macrophages, we found that chy-
mase-treated apoA-I had lost its anti-inflammatory effects 
and its ability to promote macrophage cholesterol efflux 
from human macrophages. It has been found earlier that loss 
of apoA-I/ABCA1 interaction not only prevents initiation of 
cholesterol efflux, but also initiation of the anti-inflammatory 
Figure 6. Chymase treatment does not affect the anti-inflammatory effects of D-4F on human coronary artery endothelial cells (HCAECs), 
neutrophils, and macrophages. A, HCAECs were preincubated with untreated or chymase-treated L-4F and D-4F (50 μg/mL, each) after 
which the cells were then activated with tumor necrosis factor-α (TNF-α), as described in Figure 1. Nonactivated cells (control) and TNF-
α-activated cells preincubated in only medium (buffer) were used as references. Cell-surface expression of vascular cell adhesion mol-
ecule-1 (VCAM-1) protein was determined by flow cytometry. Data represent the means±SD from 3 independent experiments performed in 
duplicate. *P<0.01; #P<0.01 (untreated L-4F or untreated D-4F vs buffer). B, Superoxide radical production by PMA (phorbol 12-myristate 
13-acetate)–activated neutrophils was determined after the cells had been preincubated for 5 min with the indicated concentrations of 
untreated or chymase-treated L-4F, D-4F, or apolipoprotein A-I (apoA-I). PMA-activated neutrophils preincubated in only medium (buf-
fer) were used as a reference (open triangles). Luminescence emitted by nonactivated neutrophils (control) was set as 1. Data are derived 
from 2 donors and represent the means±SD from 2 independent experiments, each performed in 3 to 6 wells. *P<0.01 (untreated vs 
chymase-treated L-4F, and untreated vs chymase-treated apoA-I); #P<0.01 (untreated L-4F, D-4F, or apoA-I vs buffer). C-J, Human 
monocyte–derived macrophages were differentiated into GM-Mac and M-Mac subtypes and converted into foam cells by incubation with 
acetyl low-density lipoprotein (LDL). The foam cells were then incubated for 3 h with untreated or chymase-treated D-4F (50 μg/mL, each), 
washed, and activated for 3 h with lipopolysaccharide (LPS). Nonactivated foam cells (control) and LPS-activated foam cells preincubated 
in only medium (buffer) served as references. LPS-induced mRNA levels of TNF-α, interleukin (IL)-1β, IL-6, and IL-8 in GM-Mac and M-Mac 
foam cells were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and expressed as fold changes relative to the 
control cells. Data represent the means±SD from triplicate wells and are representative of 2 independent experiments. *P<0.01; **P<0.05.
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effects of apoA-I in these cells,46,47 and moreover that silenc-
ing of ABCA1 abolishes the inhibitory effect of apoA-I on 
the production of TNF-α and other inflammatory cytokines in 
LPS-activated human macrophages.48 Moreover, apoA-I has 
been recently found to exert anti-inflammatory effects on pep-
tidoglycan polysaccharide–activated human macrophages by 
decreasing NF-κB activation in an ABCA1-dependent man-
ner.49 Thus, we infer that the present observation of the loss of 
the ability of chymase-treated apoA-I to abolish a proinflam-
matory response of macrophages to LPS treatment actually 
reflected lost interaction with macrophage ABCA1, similar 
to the loss of the apoA-I-dependent induction of cholesterol 
efflux from macrophage foam cells after chymase treatment 
of apoA-I.19 Thus, a failure to bind to macrophage ABCA1 
appears to be the molecular link between the losses of the anti-
inflammatory and the cholesterol efflux-inducing capacities of 
the C-terminally truncated apoA-I because of chymase treat-
ment. Similarly, myeloperoxidase-derived hypochlorous acid, 
which oxidizes apoA-I, impairs the ability of HDL particles 
to promote cholesterol efflux and also compromises their 
anti-inflammatory properties.50 More recently, non-enzymatic 
glycation, which induces changes in structure and in lipid-
binding activity of apoA-I,51 was also observed to impair 
both the cholesterol efflux capacity and anti-inflammatory 
properties of apoA-I.13,45 Thus, several apoA-I-modifying fac-
tors alter the structure of apoA-I in such a way that, besides 
affecting adversely its anti-inflammatory properties, they also 
impair its cholesterol efflux–inducing capacity.
In vivo studies have demonstrated that administration of 
apoA-I inhibits inflammatory responses in experimental ani-
mals, like in rabbits,16,17 mice,35 and rats49 subjected to acute 
or chronic inflammation. Actually, overexpression of human 
apoA-I in mice attenuates LPS- or high fat–induced inflam-
mation,7,8 whereas apoA-I deletion results in loss of its anti-
inflammatory actions.52 Our in vivo data in mice showed 
that proteolytic modification of apoA-I by chymase failed 
to neutralize endotoxin activity, thereby impairing its anti-
inflammatory properties in acute inflammation induced by 
LPS. Similarly, in rabbits with acute vascular inflammation, 
the anti-inflammatory properties of apoA-I in vivo have been 
found to be markedly reduced when the animals were infused 
with glycated apoA-I derived from in vitro modification or 
from patients with persistent hyperglycemia,13 so providing 
a relevant link between experimental and clinical studies. Of 
particular relevance to the present work are some recent find-
ings from other laboratories, which attribute the origins of the 
C-terminally truncated apoA-I in human plasma to mast cell–
secreted chymase or to plasmin generated during thrombolytic 
treatment of coronary patients with tissue plasminogen activa-
tor,53–55 that is, the 2 proteases also studied here. Obviously, the 
chymase-generated C-terminally truncated apoA-I must result 
from extracellular activity of chymase, that is, it requires mast 
cell degranulation with ensuing release of granule-bound chy-
mase. Regarding plasmin-generated C-terminally truncated 
apoA-I, also endogenously generated plasmin in atheroscle-
rotic lesions may be involved. Thus, given that apoA-I frag-
ments have been detected in human plasma, albeit at low 
concentrations, as a result of rapid catabolism of C-terminally 
truncated apoA-I in vivo,56 a small fraction of the lipid-free 
or lipid-poor apoA-I appears to be specifically proteolyzed in 
the extracellular compartment of human body. Regarding the 
generation of chymase-specific apoA-I degradation products 
in humans, the cardiovascular system could be one source. 
Thus, mast cells are particularly abundant in human coronary 
intima, and the number of activated mast cells in atheroscle-
rotic plaques increase with disease progression.57 Activated 
mast cells have been also demonstrated to accumulate in 
canine myocardium after ischemia and reperfusion, and more-
over, myocardial chymase activity is significantly increased 
in the acute phase of myocardial infarction in hamsters.58–60 
Importantly, the substrates for chymase, that is, the chymase-
sensitive small lipid-poor preβ-HDL particles, are enriched in 
the arterial intimal fluid and also in the peripheral lymphatic 
fluid, which among other tissues and organs, also drains the 
coronary arterial wall and the myocardium.3,4 The challenge 
is to find a suitable animal model in which chymase-specific 
apoA-I degradation products would reside in the lymphatic 
fluid draining an ischemic myocardium.
Finally, considering the demonstrated therapeutic poten-
tial of parenterally infused apoA-I in atherosclerotic coronary 
artery disease,61 the therapeutic potential of an intravenously 
infused apoA-I-containing rHDL preparation (including the 
protease-sensitive apoA-I Milano)62,63 or of an apoA-I-mimetic 
peptide could be locally compromised by extracellular pro-
teolytic activities in the target tissue, notably in an inflamed 
advanced coronary lesion. This challenge could be overcome 
by parenteral administration of an apoA-I mimetic peptide, 
such as the D-4F peptide, in which high anti-atherosclerotic 
activity is combined with an ability to resist proteolytic attack.
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Activated mast cells are present in human atherosclerotic lesions where they release chymase capable of avidly degrading lipid-free apo-
lipoprotein A-I (apoA-I) and lipid-poor species of high-density lipoprotein. Here, we report that C-terminal cleavage of apoA-I by chymase 
abolished its anti-inflammatory properties. This is the first demonstration of involvement of a pathophysiologically relevant protease in the 
regulation of a multitude of anti-inflammatory functions of apoA-I. Because atherosclerotic lesions contain a variety of extracellular proteases 
capable of C-terminally cleaving apoA-I, local proteolytic inactivation of apoA-I and lipid-poor preβ-high-density lipoprotein particles is likely. 
Therefore, the use of protease-resistant apoA-I-mimetic peptides may be of special value in the treatment of atherosclerosis.
Significance









Öörni, Mohamad Navab, Alan M. Fogelman, Matti Jauhiainen, Miriam Lee-Rueckert and Petri 
Su Duy Nguyen, Katariina Maaninka, Jani Lappalainen, Katariina Nurmi, Jari Metso, Katariina
Impairs Its Anti-Inflammatory Properties
Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase
Print ISSN: 1079-5642. Online ISSN: 1524-4636 
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Greenville Avenue, Dallas, TX 75231
is published by the American Heart Association, 7272Arteriosclerosis, Thrombosis, and Vascular Biology 
doi: 10.1161/ATVBAHA.115.306827
2015;
2016;36:274-284; originally published online December 17,Arterioscler Thromb Vasc Biol. 
Free via Open Access 
 http://atvb.ahajournals.org/content/36/2/274
World Wide Web at: 




is onlineArteriosclerosis, Thrombosis, and Vascular Biology  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Question and Answer
Permissions and Rightspage under Services. Further information about this process is available in the
which permission is being requested is located, click Request Permissions in the middle column of the Web
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for 
 can be obtained via RightsLink, a service of theArteriosclerosis, Thrombosis, and Vascular Biologyin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:













is onlineArteriosclerosis, Thrombosis, and Vascular Biology  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Question and Answer
Permissions and Rightspage under Services. Further information about this process is available in the
which permission is being requested is located, click Request Permissions in the middle column of the Web
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for 
 can be obtained via RightsLink, a service of theArteriosclerosis, Thrombosis, and Vascular Biologyin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:








Carboxyl-terminal cleavage of apolipoprotein A-I by human mast cell chymase impairs its 
anti-inflammatory properties  
 
Su Duy Nguyen1, Katariina Maaninka1, Jani Lappalainen1, Katariina Nurmi1, Jari Metso2, 
Katariina Öörni1, Mohamad Navab3, Alan M. Fogelman3, Matti Jauhiainen2 , Miriam Lee-
Rueckert1, and Petri T. Kovanen1*  
 
 
1Wihuri Research Institute, Biomedicum, Helsinki, FI-00290, Helsinki, Finland 
2National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum, 
Helsinki, Finland 
3Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of 
California, Los Angeles, CA, 90095, USA 
 
Running title: Chymase blocks anti-inflammatory effects of apoA-I 
  








ND: Not determined  
 
   Composition 
Type Shape Mobility PC: cholesterol: apoA-I Lipid: protein 
   (molar ratio) (mass ratio) 
rHDL-1 Discoidal Preβ 30:12.5:1 1:1 
rHDL-2 Discoidal Preβ 140:12.5:1 3.9:1 
rHDL-3 Discoidal Preβ 250:12.5:1 6.8:1 
HDL2 Spherical α ND ND 
HDL3 Spherical α ND ND 




Gene Forward Primers Reverse Primers Probes 
VCAM-1 5’-CGCAAACACTTTATGTCAATGTTG-3’ 5’-GATTTTCGGAGCAGGAAAGC-3’ 5’-CCAGAGATACAACCGTCTTGGTCAGCC--3’ 
ICAM-1 5’-CCCTGATGGGCAGTCAACA-3’ 5’-GCAGCGTAGGGTAAGGTTCTTG-3’ 5’-CCTCACCGTGTACTGGACTCCAGAACG-3’ 
TNFα 5’-GCTGCACTTTGGAGTGATCG-3’ 5’-GTTTGCTACAACATGGGCTACAG-3’ 5’-CCCAGGCAGTCAGATCATCTTCTCGA-3’ 
IL-1β 5’-TTACAGTGGCAATGAGGATGAC -3’ 5’-GTCGGAGATTCGTAGCTGGAT -3’ 5’-AACAGATGAAGTGCTCCTTCCAGGACC-3’ 
IL-6 5’-GAACCTTCCAAAGATGGCTGA-3’ 5’-CAAACTCCAAAAGACCAGTGATG-3’ 5’-CAGGCAAGTCTCCTCATTGAATCCAGA-3’ 
IL-8 5’-CTCTTGGCAGCCTTCCTGA-3’ 5’-GGTGGAAAGGTTTGGAGTATGTC-3’ 5’-TGGCAAAACTGCACCTTCACACAGAG-3’ 
COX-2 5’-CGAGGGCCAGCTTTCAC-3’ 5’-GGCGCAGTTTACGCTGTCTAG-3’ 5’-TGATTTAAGTCCACCCCATGGCCC-3’ 




Supplemental Figure I. SDS-PAGE analysis of apoA-I after treatment with mast 
cell- conditioned medium.  
ApoA-I (1 mg/ml) and conditioned medium, in which mature human mast cells 
generated from circulating progenitors had been activated, were incubated at 37oC for 6 
h. Incubations were performed in the absence or presence of the indicated proteinase 
inhibitors, which were added at concentrations which fully inhibited the respective 
proteases. The conditioned medium contained 0.15 µg (36 BTEE units)/ml chymase 
and co-secreted mast cell granule neutral proteases (cathepsin G, tryptase, 
carboxypeptidase A3, and granzyme B). After incubation, proteins were resolved in 
NuPAGE Novex 4-12% Bis-Tris gels and detected by Coomassie Blue or resolved in 
12.5% SDS-PAGE and immunoblotted with anti-human apoA-I polyclonal antibody or 
with anti-human apoA-I monoclonal antibodies recognizing either a carboxyl-terminal 
(amino acids 211-220) or an amino-terminal (amino acids 2-8) region of apoA-I. Similar 
results were obtained using conditioned medium from mature mast cells derived from 





Supplemental Figure II. Non-denaturing polyacrylamide gradient gel 
electrophoresis (NDGGE) analysis of rHDLs upon chymase treatment 
A, Aliquots of untreated and chymase-treated (A-I)rHDL were electrophoresed by 4-
30% NDGGE. The gels were stained with Coomassie blue. 
B, The profiles of particle size distribution were analyzed by NIH ImageJ software. The 
boxes show the areas in which the differences between each untreated and 




Supplemental Figure III. Chymase treatment of mature HDL does not affect its 
ability to inhibit VCAM-1 expression on activated HCAECs.  
A, HDL2 or HDL3 (1 mg/ml) were incubated in the absence (untreated) or presence of 
recombinant human chymase (40 BTEE units/ml) for 6 h. The proteins in the incubation 
mixture were resolved in 12.5% SDS-PAGE and detected by Coomassie Blue or 
immunoblotted with anti-human apoA-I polyclonal antibody.  
B, HCAECs were preincubated for 16 h with untreated or chymase-treated HDL2 or 
HDL3 (50 µg/ml, each), and then stimulated with TNFα (10 ng/ml) for 5 h. Non-activated 
cells (control) and TNFα-activated cells preincubated in only medium (buffer) acted as 
references. VCAM-1 surface protein expression levels were analyzed by flow cytometry 
(% of buffer). Data represent the means ± SD from 3 independent experiments 
performed in duplicate. #p< 0.01 (untreated vs. buffer).  
  
 
Supplemental Figure IV. Treatment of apoA-I with plasmin or cathepsin S impairs 
its ability to attenuate proinflammatory responses in activated HCAECs.  
A, ApoA-I (1 mg/ml) was incubated for 1 h in the absence or presence of chymase (40 
BTEE U/ml = 0.5 µg/ml), plasmin (0.1 U/ml = 50 µg/ml), or cathepsin S (0.15 U/ml = 5 
µg/ml) in TNE buffer. The untreated and protease-treated apoA-I were resolved in 
12.5% SDS-PAGE and detected by Coomassie Blue or immunoblotted with anti-human 
apoA-I polyclonal antibody or with anti-human apoA-I monoclonal antibody recognizing 
either a carboxyl-terminal (amino acids 211-220) or an amino-terminal (amino acids 2-8) 
region of apoA-I. 
B, HCAECs were preincubated for 16 h with untreated or protease-treated apoA-I (50 
µg/ml, each), and then stimulated with TNFα (10 ng/ml) for 5 h. Non-activated cells 
(control) and TNFα-activated cells preincubated in only medium (buffer) acted as 
references. Cell surface expression of VCAM-1 was determined by flow cytometry (top 
panel). Data represent the mean ± SD from three to four independent experiments 
performed in duplicate. In a separate experiment, HCAECs that had been treated as 
described above were incubated for 1 h with fluorescently labeled THP-1 macrophages. 
Nonadherent THP-1 cells were removed by gentle washing and the fluorescence of 
HCAECs-bound THP-1 cells was measured. The fluorescence signals of TNF-
stimulated HCAECs were expressed as percentages of the basal signal from the control 
cells. Data shown in the panels represent the means ± SEM from 3 independent 
experiments performed in triplicate wells. * p< 0.01 (untreated vs. protease-treated);# p< 
0.01 (untreated vs. buffer).   
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Materials and Methods 
 
Preparation of apoA-I-containing reconstituted HDL [(A-I)rHDL] 
 Lipid-free apoA-I was purified according to a previously published procedure.1 Three 
types of (A-I)rHDL particles with varying degrees of lipidation were prepared by the 
cholate dialysis method.2 The molar ratio of egg yolk phosphatidyl choline (PC): 
cholesterol: apoA-I was 30:12.5:1, 140:12.5:1, and 250:12.5:1 for rHDL-1, rHDL-2, and 
rHDL-3, respectively. The proteoliposome preparations were dialyzed extensively 
against endotoxin-free Tris-buffered saline (pH 7.4) at 4°C, stored at 4°C, and used 
within a week. All (A-I)rHDLs were found to be heterogeneous in size and they exhibited 
preβ-mobility (Supplemental Table I).  
  
Isolation of high-density lipoproteins  
 HDL2 (d = 1.063-1.125 g/ml) and HDL3 (d = 1.125-1.210 g/ml) were prepared from 
freshly isolated plasma of healthy volunteers obtained from the Finnish Red Cross by a 
rapid sequential flotation ultracentrifugation (UC) using KBr for density adjustment.3 This 
short UC method carried out in a Beckman OptimaTM TLX system Table Top 
Ultracentrifuge with a Beckman fixed-angle rotor (TLA100.3) at 541,000 g yields HDL 
preparations devoid of preβ-migrating particles.4 The amounts of HDL are expressed in 
terms of their protein concentrations, which were determined by BCA protein assay kit 
(Pierce, Rockford, IL) using bovine serum albumin as standard. 
 
Treatment of lipid-free apoA-I, (A-I)rHDLs, HDL2, HDL3, and of apoA-I mimetic 
peptides L-4F and D-4F by purified proteases 
 Lipid-free apoA-I, (A-I)rHDL, HDL2, HDL3, or the apoA-I mimetic peptides L-4F and 
D-4F (1 mg/ml, each) were incubated for 6 h in the absence (untreated) or the presence 
of 40 BTEE units/ml (units of activity as described by Woodbury5) of recombinant 
human chymase (kindly provided by Teijin Ltd. Hino, Tokyo, Japan) in 5 mM Tris buffer 
containing 150 mM NaCl and 1 mM EDTA (TNE buffer, pH 7.4) for 6 h at 37oC. Lipid-
free apoA-I (1 mg/ml) was also incubated for 1 h with 40 BTEE units/ml of chymase, 0.1 
U/ml of plasmin (Sigma:  P1867) or 0.15 U/ml of cathepsin S (Calbiochem: 219343) in 
TNE buffer. After the incubations, chymase and plasmin were fully inhibited by adding 
soybean trypsin inhibitor (SBTI, final concentration, 100 µg/ml),6, 7 whereas cathepsin S 
was inhibited by adding E-64 (Sigma: E3132, final concentration, 10 µM).8 Aliquots of 
the incubation mixtures containing the various untreated and protease-treated apoA-I 
species were subjected to 12.5% SDS-PAGE analysis under reducing conditions. The 
protein bands were stained with Coomassie Blue, or were transferred to nitrocellulose 
and immunoblotted with anti-human apoA-I polyclonal antibody, or with anti-human 
apoA-I monoclonal antibodies recognizing either a C-terminal region (residues 211–
220) (MAb 4.1; kindly provided by Drs. Noel Fidge and Dmitri Sviridov, Prahran, 
Australia) or the N-terminus (residues 2–8) (MAb 4H1; kindly provided by Dr. Yves 
Marcel, Ottawa, Canada) of apoA-I. Both untreated and protease-treated (A-I)rHDL 
were further characterized by non-denaturing gradient gel electrophoresis (NDGGE) to 
assess HDL particle size distribution upon chymase modification. The aliquots were 
loaded onto self-prepared 4–30% polyacrylamide gradient gels (8.0 cm × 8.0 cm) and 
run at 125 V under nondenaturing conditions overnight at 4°C to reach equilibrium and 
then stained with Coomassie blue.4 HDL particle size was determined based on the use 
of high-molecular-weight electrophoresis calibration standards as molecular size 
markers. The intensities of the bands and particle size distribution profiles were 






Proteolysis of lipid-free apoA-I by human mast cell-conditioned medium 
 Mature human mast cells were isolated and cultured as described previously.9 At 
week 9 of culture, 2 x106 mast cells were stimulated with 1 µM calcium ionophore 
(A23187; Sigma-Aldrich, St. Louis, MO, USA) in DPBS containing 100 ng/ml kit ligand 
(KITLG). Mast cell stimulation induces secretion of a mixture of heparin proteoglycans, 
neutral proteases, and other active compounds into cell culture medium. After 30 min of 
stimulation, the mast cells were sedimented, the conditioned medium was collected and 
stored at -80 °C until used. The activity and concentration in the conditioned medium of 
chymase5 and other neutral proteases10 were determined as reported previously.  Lipid-
free apoA-I (1 mg/ml) was incubated for 6 h at 37oC in PBS buffer (pH 7.4) in the 
absence or presence of conditioned medium (containing 40 or 120 BTEE units/ml 
chymase activity). After the incubations, chymase activity was fully inhibited by addition 
of SBTI, and aliquots of the incubation mixtures were subjected to 12.5% SDS-PAGE 
analysis under reducing conditions as described above.  
 To determine individual contributions of the various proteases present in the mast 
cell-conditioned medium to apoA-I degradation, each protease was fully inhibited by 
pre-incubating the conditioned medium for 30 min on ice in the presence of specific 
protease inhibitors at the following final concentrations: diphenyl Nα-benzoxycarbonyl-L-
Arg-Glu-Thr-PheP-phosphonate (RETF-(OPh)) (chymase inhibitor; kindly provided by 
Dr. Gunnar Pejler, Uppsala, Sweden, 2.3 µM); cathepsin G inhibitor I, (cathepsin 
inhibitor, Calbiochem, 500 nM); leupeptin (tryptase inhibitor, Sigma, 50 µg/ml); 
carboxypeptidase inhibitor from potato tuber (carboxypeptidase A3 inhibitor, Sigma, 25 
µg/ml); and benzyloxycarbonyl-Ala-Ala-Asp-chloromethylketone (granzyme B inhibitor, 
Enzo Life Science, 20 µM). Next, aliquots of various inhibitor-pretreated conditioned 
media which contained chymase (final concentration, 36 BTEE unit/ml corresponding to 
0.15 µg/ml) and co-secreted mast cell granule neutral proteases (cathepsin G, tryptase, 
carboxypeptidase A3, and granzyme B) were added to apoA-I (final concentration, 1 
mg/ml) in PBS, and incubated for 6 h at 37oC. Finally, the aliquots were subjected to 
high-resolution electrophoresis gel analysis using NuPAGE Novex 4-12% Bis-Tris gels. 
 
Culture of human coronary artery endothelial cells   
 HCAECs (PromoCell) were cultured in Endothelial Cell Growth Medium MV (Basal 
Medium; Catalog Number C-22220, PromoCell) supplemented with 5% fetal calf serum, 
0.4% endothelial cell growth supplement, 10 ng/ml epidermal growth factor, 90 µg/ml 
heparin, 1 μg/ml hydrocortisone (Supplement pack, Catalog Number C-39220, 
PromoCell), and 100 U/mL penicillin streptomycin solution, and 50 ng/ml amphotericin B 
to yield Complete Medium in T-75 flask according to according to the manufacturer's 
instructions. Confluent HCAECs were washed with 15 ml of PBS, trypsinized, and 
replated in Complete Medium, as described below. Experiments were performed with 
cells of 5-8th passage from two donors. HCAECs were seeded at a density of 0.5-1 x 
105 cells/well in 12 well plates (1.5 ml medium/well) and cultured for 2-3 days until the 
cells reached 80-85% confluency. Then the HCAECs were washed with Complete 
Medium (1 ml) and replaced with Basal Medium supplemented with protease inhibitors 
(SBTI, 100 µg/ml or E-64, 10 µM) and pre-incubated with the untreated or protease-
treated apoA-I species or the mimetic peptides L-4F or D-4F (50 µg/ml, each) for 16 h, 
followed by TNFα (10 ng/ml) stimulation for 5 h. The expression of VCAM-1 and other 
proinflammatory genes was evaluated by quantitative RT-PCR and the cell surface 








Quantitative real-time PCR (qRT-PCR) 
 Total RNA was isolated from cultured HCAECs or human macrophage foam cells 
(RNeasy kit, QIAGEN). Nucleic acid concentrations were determined by NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Purified RNA (0.5 
µg) was used to generate cDNA using RT-PCR (M-MLV reverse transcriptase, 
Promega). Oligonucleotide sequences of the primers for detection of GAPDH (internal 
control), VCAM-1, ICAM-1, TNFα, IL-1β, IL-6, IL-8, and COX-2 are shown in 
supplemental Table II. cDNA was diluted 1:5 and analyzed in duplicates on 96-well 
optical plates using the TaqMan Gene Expression Master Mix (Applied Biosystems). 
The thermal cycling parameters were as follows: thermal activation for 10 min at 95°C, 
and 40 cycles of PCR (melting for 15s at 95°C and annealing/extension for 1 min at 
60°C). Relative quantification was calculated with the 2-(ΔCT) method 11 and normalized 
to GAPDH. 
 
Flow cytometric analysis of VCAM-1 
 HCAECs were washed with 1 ml cold PBS, detached from culture plates according 
to the manufacturer's instructions, and centrifuged at 300 x g for 5 min at 4oC. Cells 
were then washed two times with FACS buffer (PBS buffer containing 0.02% sodium 
azide and 0.5% bovine serum albumin), resuspended in 100 µl of FACS buffer 
containing PE-labeled mouse anti-human VCAM-1 (BD PharmingenTM), and incubated 
at 4oC in the dark for 30 min. At the end of incubation, the cells were washed 3 times 
with FACS buffer, and then fixed in FACS buffer containing 2% formaldehyde for 20 min 
at 4oC. The expression of cell surface VCAM-1 was analyzed by using a LSR II flow 
cytometer (BD Pharmingen). The PE-labeled mouse IgG1 isotype non-specific antibody 
was used as a negative control (BD Pharmingen). Cells were gated, and data were 
obtained from fluorescence channels in a logarithmic mode. Data from 10,000 cells 
were collected, and processed using the CellQuest program (BD Biosciences).  
 
Adhesion of THP-1 monocytes to HCAECs 
 The ability of THP-1 monocytes to adhere to TNFα-activated HCAECs was 
determined using Vybrant cell adhesion assay kit (Molecular Probes). Typically, 
HCAECs (80-85% confluency) were washed with Complete Medium and replaced with 
Basal Medium supplemented with protease inhibitors (SBTI, 100 µg/ml or E-64, 10 µM) 
and incubated for 16 h with untreated or the various protease-treated apoA-I and (A-
I)rHDL (50 µg/ml, each), followed incubation for 5 h with TNFα (10 ng/mL). After 
stimulation, the HCAECs were washed two times with HBSS culture medium 
(BioWhittaker, Lonza, Switzerland). Concurrently, THP-1 cell suspensions were 
adjusted to 5 x 106 cells/ml and fluorescently labeled with Calcein AM (final 
concentration, 5 µM; 30 min,) in PBS. THP-1 cells were washed two times with PBS to 
remove nonincorporated calcein. The fluorescently labeled-THP-1 cells were 
resuspended in HBSS culture medium and added (50,000 cells/well) to HCAECs. After 
incubation for 60 min at 37oC, non-adherent cells were removed by gently washing four 
times with HBSS culture medium and fluorescence of HCAEC-bound THP-1 cells was 
measured using VICTOR3 multilabel plate reader (Perkin Elmer, Finland) at an 
excitation wavelength of 495 nm and an emission wavelength of 515 nm. The 
fluorescence signal of basal untreated HCAECs (control) was designated as 100%.  
 







 Monocyte transmigration across an endothelial cell monolayer was determined using 
the CytoSelect™ Leukocyte Transendothelial Migration Assay kit (Cell Biolabs, Inc., 
San Diego, USA) according to manufacturer’s recommendations with some 
modifications. Briefly, HCAECs (150,000 cells) were added to the upper side of porous 
filter inserts (6.5 mm insert diameter, 3 μm pore size, Corning Life Sciences, NY, USA) 
precoated with rat-tail collagen (10 µg/cm2: BD Biosciences) and cultured in Complete 
Medium for 2-3 days to obtain tight confluent monolayers of HCAECs. Thereafter, the 
HCAECs were washed, and incubated for 16 h in Basal Medium supplemented with the 
protease inhibitor SBTI (100 µg/ml), and either untreated or chymase-treated apoA-I 
(final concentration, 50 µg/ml) added to either the upper (apical) or lower (basolateral) 
transwell compartment. The HCAECs were activated by adding TNFα (10 ng/ml) to the 
apical compartment of the transwell system. After a 5 h stimulation, the HCAECs were 
washed twice with HBSS culture medium (BioWhittaker, Lonza, Switzerland), and 
fluorescently labeled-THP-1 cells (200,000 cells in HBSS culture medium) were added 
to the apical compartment and allowed to migrate for 2 hours. Then, media were 
carefully aspirated from the apical compartment and non-migratory cells were gently 
removed by using cotton swabs. The cells in the insert and in the basolateral medium 
(together comprising the “transmigrated cells”) were transferred to new wells containing 
lysis buffer and incubated for 10 min at room temperature. 200 µl aliquots of lysates 
were transferred to a 96-well plate for fluorescence measurement. The fluorescence 
signal of transmigrated cells under control condition (control) was designated as 100%. 
The net yield of transmigrated cells under control condition was within the 6.5% - 23% 
range of the total number of THP-1 cells added. 
 
NF-κB nuclear translocation assay 
 HCAECs (80-85% confluency) grown in Complete Medium were washed with 
Complete Medium and after which the cells received Basal Medium supplemented with 
SBTI (100 µg/ml) and either untreated or chymase-treated apoA-I (final concentration, 
50 µg/ml, each) for 16 h and finally stimulated with TNFα (10 ng/mL) for 15 min. After 
the incubation, cells were washed with cold PBS, scraped into cold PBS supplemented 
with phosphatase inhibitors, and nuclear extracts were prepared using the nuclear 
extract kit (Active Motif, Rixenart, Belgium) according to the manufacturer's instructions. 
To detect NF-κB activation, nuclear extracts (2.0 μg) were analyzed using the TransAM 
NF-κB p65 kit (Active Motif, Rixenart, Belgium) according to the manufacturer's 
instructions.  
 
Radiolabeling and binding of apoA-I to HCAECs  
 ApoA-I was labeled with 125I using Iodination Beads (Pierce, Rockville, IL) and Na125I 
(Thermo Scientific) according to the manufacturer's instructions to yield final specific 
activities of 700-800 dpm/ng protein. To study the effect of chymase on apoA-I binding, 
125I-apoA-I was incubated for 6 h at 37oC in the absence or the presence of chymase. 
After addition of SBTI for full inhibition of chymase activity, the binding assay of 125I-
apoA-I was conducted as described previously12 with some modifications. Briefly, 
HCAECs were seeded at a density of 2.5- 5 x 104 cells/well in 24 well plates (1.0 ml 
medium/well) and cultured for 2-3 days until the cells reached 90-95% confluency. Then 
the cells were chilled on ice, and kept at 4oC throughout the entire experiment. The cells 
were washed once with Complete Medium, and incubated with the untreated or 
chymase-treated 125I-apoA-I at the indicated concentrations in 0.5 ml Basal Medium 
containing 0.5 % fatty acid-free BSA in the absence or presence of a 40-fold excess of 






0.5% fatty acid-free BSA, followed by three washes with PBS. The cells were then 
solubilized in 0.25 ml of 0.2 M NaOH for 1 h at room temperature, the radioactivity was 
measured using Wallac Liquid Scintillation Counter (Wallac, Finland), and the protein 
content was determined using a BCA protein assay kit (Pierce, Rockford, IL). High-
affinity binding was calculated by subtracting the values obtained in the presence of 40-
fold excess of unlabeled apoA-I (non-specific binding) from those obtained in its 
absence (total binding). 
 
Culture of primary human monocyte-derived macrophages  
 Human monocytes were isolated from buffy coats (Finnish Red Cross Blood 
Transfusion Center, Helsinki, Finland) by centrifugation in Ficoll-Paque gradient as 
described.13 Washed cells were suspended in DMEM supplemented with 100 U/ml 
penicillin and 100 µg/ml streptomycin, counted, and seeded on 24 well-plates (1.5 
million cells per well). After 1 h incubation, non-adherent cells were removed and the 
medium was replaced with macrophage-SFM medium (Gibco) supplemented with 1% 
penicillin-streptomycin and 10 ng/ml of granulocyte macrophage colony-stimulating 
factor (GM-CSF) or 50 ng/ml of macrophage colony-stimulating factor (M-CSF) (Biosite, 
San Diego, USA). The cells were cultured for 7 days in the presence of GM-CSF or M-
CSF to allow them to differentiate into GM-CSF macrophages (GM-Mac) or M-CSF 
macrophages (M-Mac) as described previously.14 The medium was then changed every 
2 to 3 days throughout the culture period. The differentiated macrophages were 
incubated for 24 h in DMEM containing 25 μg/ml of acetylated LDL to generate 
cholesterol-loaded foam cells. The cells were washed with PBS twice, replaced with 
DMEM supplemented with SBTI (100 µg/ml), and incubated with untreated or chymase-
treated apoA-I (50 µg/ml, each) for 3 h. To prevent the binding of LPS to apoA-I,15, 16 
macrophage foam cells which had been preincubated with the untreated apoA-I or the 
chymase-treated apoA-I, were extensively washed, and then challenged with 100 ng/ml 
of LPS from Escherichia coli serotype 0111:B4 (Sigma: Finland) for 3 h. Cells were 
collected and the expression of proinflammatory genes was evaluated by qRT-PCR.  
In parallel experiments, cholesterol efflux from macrophage foam cells was measured. 
For this purpose, the cholesterol-loaded foam cells were incubated in DMEM 
supplemented with SBTI (100 µg/ml) containing either untreated or chymase-treated 
apoA-I (50 µg/ml, each) as cholesterol acceptors. After incubation for 3 h, cholesterol 
efflux were determined, as described previously.4 
 
Effects of chymase-treated apoA-I, L-4F, and D-4F on PMA-activated neutrophils 
 Human neutrophils were isolated from freshly prepared buffy coats by a standard 
method of centrifugation in a Ficoll Hypaque gradient prior to dextran sedimentation.17 
After dextran sedimentation, all steps were carried out at 4°C. Any remaining 
erythrocytes were lysed in ice-cold de-ionized water and tonicity was restored by the 
addition of equal volume of 1.8% NaCl. Cells were washed, adjusted to 4 x 106 cells/ml 
in HBSS buffer (pH 7.4) (BioWhittaker, Lonza, Switzerland), maintained at 4oC, and 
used within 2 h after the isolation. The isolated neutrophils contained > 95% viable cells, 
as determined by the NucleoCounter NC-200 (ChemoMetec A/S).  
 Superoxide anion production was detected by lucigenin-enhanced 
chemiluminescence assay.18 The freshly isolated neutrophils (100,000 cells/well) were 
preincubated with increasing concentrations of the untreated or chymase-treated apoA-
I, L-4F, or D-4F for 5 min at room temperature in 96-well plates in 0.1 ml HBSS solution, 
followed by the addition of lucigenin (final concentration, 10 µM). After 2 min incubation 






concentration, 100 nM) for 10 min. The plates were protected from light and the 
luminescence signal (counts per second) was determined using a VICTOR3 multilabel 
plate reader (Perkin Elmer, Finland). The luminescence signal of basal unstimulated 
neutrophils (control) was designated as 1.  
The effect of proteolysis on anti-inflammatory properties of apoA-I in vivo
 Untreated and chymase-treated apoA-I (1 mg/ml) were prepared in PBS buffer 
(BioWhittaker, Lonza, Switzerland), as described above. Thus, apoA-I was incubated in 
the absence or presence of recombinant human chymase, after which PMSF (final 
concentration, 1 mM) was added to the incubation mixture to irreversibly inhibit 
chymase. The unbound PMSF and small fragments of apoA-I were removed by 
extensive dialysis against PBS buffer (BioWhittaker, Lonza, Switzerland) at 4oC using a 
dialysis membrane with molecular weight cutoff of 12 000–14 000 Da. The untreated 
and chymase-treated apoA-I (0.5 mg/ml) were mixed with LPS (50 µg/ml) and incubated 
at room temperature for 15-30 min before injection into mice.  
 Female C57BL/6J mice (aged 18-27 weeks) from Harlan Laboratories (Venray, the 
Netherlands) were housed 3-5 per cage under controlled conditions for the light/dark 
cycle, temperature, and humidity. The animals were kept in the same animal facility for 
at least 1 week before the experiments. Mice were fed a standard chow diet (2016 
Teklad Global, Harlan Laboratories), and food and water were provided ad libitum. 
Animal experiments and the protocols were approved by The Finnish National Animal 
Experiment Board. Mice (6-8 per group) were randomized to receive a 400 µl 
intraperitoneal injection of saline vehicle (PBS), LPS (1 mg/kg: Escherichia coli serotype 
0111:B4; Sigma), LPS (1 mg/kg) plus apoA-I (10 mg/kg), or LPS (1 mg/kg) plus 
chymase-treated apoA-I (10 mg/ml). Three hours after the injection, the animals were 
terminally anesthesized with isoflurane and blood was collected by cardiac puncture for 
determination of proinflammatory mediators. The levels of TNFα and IL-1β in the serum 
were quantified by using ELISA kits according to the manufacturer’s instructions (R&D 
Systems). Endotoxin activity of LPS and of mixtures of LPS with apoA-I or chymase-
treated apoA-I were measured by the limulus amoebocyte lysate (LAL) assay (Lonza 
group ltd., Switzerland), as described in a previous study.19  
 Statistical analysis 
 Data are reported as means ± SD. Groups were compared using one-way ANOVA 
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